How to cure the flu with a new vaccine
Health officials say they’ve found a way to make a new flu vaccine that can be injected directly into the body, rather than being injected through the nose.
The technique could make the vaccine more effective at stopping the flu, which has killed more than 20 million people worldwide.
Health officials said they’ve identified a protein in the vaccine that prevents it from triggering the flu.
The vaccine was developed by a company that developed a flu vaccine in the 1990s.
It’s called B-5 and was initially designed to treat people with chronic, autoimmune disorders.
But it’s now being used for people with mild or moderate flu symptoms who have had previous exposure to the virus.
“The new vaccine that we’ve developed uses the same mechanism as B-1, B-2, B5, and B6 flu vaccines to target the influenza virus and is able to protect people against this pandemic pandemic flu,” Dr. Tom Phelan, chief medical officer for the U.S. Centers for Disease Control and Prevention, said in a statement.
The CDC also released a video showing how the vaccine works.
The video shows how a small portion of the vaccine is injected into the nose, where it’s absorbed by the immune system.
The remaining portion is then injected into a muscle that is activated by the virus and triggers the immune response.
“We’ve created an adjuvant that is targeted to this type of immune response and is not going to trigger the flu,” Phelman said.
People who get the vaccine within 48 hours will experience the flu symptoms for up to two weeks.
If they have been exposed to the flu in the past, they can still get the flu vaccine within 24 hours, but will have to wait six weeks to get the new vaccine.
People with the flu should take the vaccine as soon as possible and continue to have regular appointments with their doctor to check their immune system, which should help them stay healthy, Phelans statement said.
The new vaccine is currently being tested on animals and will be available for purchase in July.
It also has an FDA-approved safety profile, meaning that it’s unlikely to cause a fatal reaction in humans.
The agency did not say how many people have been vaccinated so far, but said that it has been tested in two large groups of people.
“People who have been tested and have had no adverse reactions have shown excellent response rates,” Dr, Stephen M. Hwang, director of the CDC’s influenza vaccine program, said.